Chemopreventive efficacy of atorvastatin against nitrosamine-induced rat bladder cancer: Antioxidant, anti-proliferative and anti-inflammatory properties

International Journal of Molecular Sciences

Volumn 13, Issue 7, 2012, Pages 8482-8499

  Parada, Belmiro ^a,b   Reis, Flávio ^a   Pinto, Ângela ^a   Sereno, José ^a   Xavier Cunha, Maria ^b   Neto, Paula ^b   Rocha Pereira, Petronila ^c   Mota, Alfredo ^b   Figueiredo, Arnaldo ^b   Teixeira, Frederico ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Anti inflammatory; Anti proliferative; Antioxidant; Atorvastatin; Bladder cancer; Chemoprevention

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CD31 ANTIGEN; CREATINE KINASE; CREATININE; KI 67 ANTIGEN; MALONALDEHYDE; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UREA; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLADDER CANCER; CANCER PREVENTION; CARCINOMA IN SITU; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPLASIA; HISTOLOGY; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; RAT; TUMOR VOLUME; ANIMAL; BLADDER; BLOOD; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; URINARY BLADDER NEOPLASMS; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BUTYLHYDROXYBUTYLNITROSAMINE; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; HEPTANOIC ACIDS; MALE; OXIDATIVE STRESS; PYRROLES; RATS, WISTAR; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84864363626     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13078482     Document Type: Article

References (55)

1. Grasso, M. Bladder cancer: A major public health issue. Eur. Urol. Suppl. 2008, 7, 510-515.
2. Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M.; Boyle, P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007, 18, 581-592.
3. Kirkali, Z.; Chan, T.; Manoharan, M.; Algaba, F.; Busch, C.; Cheng, L.; Kiemeney, L.; Kriegmair, M.; Montironi, R.; Murphy, W.M.; et al. Bladder cancer: Epidemiology, staging, grading and diagnosis. Urology 2005, 66, 4-34.
4. Sylvester, R.J.; van der Meijden, A.P.; Oosterlinck, W.; Witjes, J.A.; Bouffioux, C.; Denis, L.; Newling, D.W.; Kurth, K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006, 49, 466-477.
5. Malkowicz, S.B.; van Poppel, H.; Mickisch, G.; Pansadoro, V.; Thüroff, J.; Soloway, M.S.; Chang, S.; Benson, M.; Fukui, I. Muscle-invasive urothelial carcinoma of the bladder. Urology 2007, 69, 3-16.
6. Zeegers, M.P.; Tan, F.E.; Dorant, E.; van den Brandt, P.A. The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies. Cancer 2000, 66, 4-34.
7. Kogevinas, M.; 't Mannetje, A.; Cordier, S.; Ranft, U.; González, C.A.; Vineis, P.; Chang-Claude, J.; Lynge, E.; Wahrendorf, J.; Tzonou, A.; et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Contr. 2003, 14, 907-914.
8. Wolff, D.J. The genetics of bladder cancer: A cytogeneticist's perspective. Cytogenet. Genome Res. 2007, 118, 177-181.
9. Pelucchi, C.; La Vecchia, C. Alcohol, coffee, and bladder cancer risk: A review of epidemiological studies. Eur. J. Cancer Prev. 2009, 18, 62-68.
10. Kunze, E.; Schauer, A.; Schatt, S. Stages of transformation in the development of Nbutyltransitional cell carcinomas in the urinary bladder of rats. Z. Krebsforsch. Klin. Onkol. 1976, 87, 139-160.
11. Oliveira, P.A.; Colaço, A.; de la Cruz, L.F.; Lopes, C. Experimental bladder carcinogenesis-rodent models. Exp. Oncol. 2006, 28, 2-11.
12. Fukushimam, S.; Hirose, M.; Tsuda, H.; Shirai, T.; Hirao, K. Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl) nitrosamine. Gann 1976, 67, 81-90.
13. Hameed, D.A.; el-Metwally, T.H. The effectiveness of retinoic acid treatment in bladder cancer: Impact on recurrence, survival and TGF-alpha and VEGF as end-point biomarkers. Canc. Biol. Ther. 2008, 7, 92-100.
14. Parada, B.; Reis, F.; Figueiredo, A.; Nunes, P.; Teixeira-Lemos, E.; Garrido, P.; Sereno, J.; Pinto, R.; Cunha, M.F.; Neto, P.; et al. Inhibition of bladder tumor growth by sirolimus in an experimental carcinogenesis model. BJU Int. 2011, 107, 135-143.
15. Parada, B.; Sereno, J.; Reis, F.; Teixeira-Lemos, E.; Garrido, P.; Pinto, A.F.; Cunha, M.F.; Pinto, R.; Mota, A.; Figueiredo, A.; et al. Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biol.Ther. 2009, 8, 1615-1622.
16. Demierre, M.F.; Higgins, P.; Gruber, S.B.; Hawk, E.; Lippman, S.M. Statins and cancer prevention. Nature 2005, 5, 930-942.
17. Brown, A.J. Cholesterol, statins and cancer. Clin. Exp. Pharmacol. Physiol. 2007, 34, 135-141.
18. Sassano, A.; Platanias, L.C. Statins in tumor suppression. Cancer Lett. 2008, 260, 11-19.
19. Liao, J.K.; Laufs, U. Pleiotropic effects of statins. Ann. Rev. Pharmacol. Toxicol. 2005, 45, 89-111.
20. Schöenbeck, U.; Libby, P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as anti-inflammatory agents? Circulation 2004, 109, 18-26.
21. Wassmann, S.; Laufs, U.; Müller, K.; Konkol, C.; Ahlbory, K.; Bäumer, A.T.; Linz, W.; Böhm, M.; Nickenig, G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 300-305.
22. Tanaka, K.; Honda, M.; Takabatake, T. Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation. Clin. Exp. Pharmacol. Physiol. 2004, 31, 360-364.
23. Dulak, J.; Józkowicz, A. Anti-angiogenic and anti-inflammatory effects of statins: Relevance to anti-cancer therapy. Curr. Cancer Drug Targets 2005, 5, 579-594.
24. Kusama, T.; Mukai, M.; Iwasaki, T.; Tatsuta, M.; Matsumoto, Y.; Akedo, H.; Inoue, M.; Nakamura, H. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002, 122, 308-317.
25. Hamilton, R.J.; Freedland, S.J. Rationale for statins in the chemoprevention of prostate cancer. Curr. Urol. Rep. 2008, 9, 189-196.
26. Calabro, A.; Tai, J.; Allen, S.L.; Budman, D.R. In vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: Potential implications in acute leukemia. Anti-cancer Drugs 2008, 19, 705-712.
27. Schmidmaier, R.; Simsek, M.; Baumann, P.; Emmerich, B.; Meinhardt, G. Synergistic antimyeloma effects of zoledronate and simvastatin. Anti-cancer Drugs 2006, 17, 621-629.
28. Kamat, A.M.; Nelkin, G.M. Atorvastatin: A potential chemopreventive agent in bladder cancer. Urology 2005, 66, 1209-1212.
29. Kaye, J.A.; Jick, H. Statin use and cancer risk in the General Practice Research Database. Br. J.Cancer 2004, 90, 635-637.
30. Kitayama, J.; Hatano, K.; Kaisaki, S.; Suzuki, H.; Fujii, S.; Nagawa, H. Hyperlipidaemia is positively correlated with lymph node metastasis in men with early gastric cancer. Br. J. Surg.2004, 91, 191-198.
31. Manickavasagam, S.; Ye, Y.; Lin, Y.; Perez-Polo, R.J.; Huang, M.H.; Lui, C.Y.; Hughes, M.G.; McAdoo, D.J.; Uretsky, B.F.; Birnbaum, Y. The cardioprotective effect of a statin and cilostazol combination: Relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc. Drugs. Ther. 2007, 21, 321-330.
32. Birnbaum, Y.; Lin, Y.; Ye, Y.; Merla, R.; Perez-Polo, J.R.; Uretsky, B.F. Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J. Cardiovasc. Pharmacol. Ther. 2008, 13, 72-79.
33. Schmechel, A.; Grimm, M.; El-Armouche, A.; Höppner, G.; Schwoerer, A.P.; Ehmke, H.; Eschenhagen, T. Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Cardiovasc. Res. 2009, 82, 100-106.
34. Wierzbicki, A.S.; Poston, R.; Ferro, A. The lipid and non-lipid effects of statins. Pharmacol. Ther. 2003, 99, 95-112.
35. Chan, K.K.W.; Oza, A.M., Siu, L.L. The statins as anticancer agents. Clin. Canc. Res. 2003, 9, 10-19.
36. Bababeygy, S.R.; Polevaya, N.V.; Youssef, S.; Sun, A.; Xiong, A.; Prugpichailers, T.; Veeravagu, A.; Hou, L.C.; Steinman, L.; Tse, V. HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model. Anticancer Res. 2009, 29, 4901-4908.
37. Jánosi, J.; Sebestyén, A.; Bocsi, J.; Barna, G.; Nagy, K.; Vályi-Nagy, I.; Kopper, L. Mevastatin-induced apoptosis and growth suppression in U266 myeloma cells. Anticancer Res. 2004, 24, 1817-1822.
38. Fujita, J.; Yoshida, O.; Yuasa, Y.; Rhim, J.S.; Hatanaka, M.; Aaronson, S. Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumors. Nature 1984, 309, 464-466.
39. Oxford, G.; Theodorescu, D. The role of Ras superfamily proteins in bladder cancer progression. J.Urol. 2003, 170, 1987-1993.
40. Björkhem-Bergman, L.; Acimovic, J.; Torndal, U.B.; Parini, P.; Eriksson, L.C. Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. Anticancer Res. 2010, 30, 1105-1112.
41. Jain, M.K.; Ridker, P.M. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 2005, 4, 977-987.
42. Paumelle, R.; Staels, B. Peroxisome proliferators-activated receptors mediate pleiotropic actions of statins. Circ. Res. 2007, 100, 1394-1395.
43. Michalik, L.; Desvergne, B.; Wahli, W. Peroxisome proliferators-activated receptors and cancer: Complex stories. Nat. Rev. 2004, 4, 61-70.
44. Mansure, J.J.; Nassim, R.; Kassouf, W. Peroxisome proliferator-activated receptor gamma in bladder cancer: A promising therapeutic target. Cancer Biol. Ther. 2009, 8, 6-15.
45. Zheng, X.; Cui, X.X.; Avila, G.E.; Huang, M.T.; Liu, Y.; Patel, J.; Kong, A.N.; Paulino, R.; Shih, W.J.; Lin, Y.; et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin. Cancer Res. 2007, 13, 5480-5487.
46. Keller, J.J.; Giardiello, F.M. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Canc. Biol. Ther. 2003, 2, S140-S149.
47. El Gehani, K.; Al-Kikhia, L.; Mansuri, N.; Syrjänen, K.; Al-Fituri, O.; Elzagheid, A. Angiogenesis in urinary bladder carcinoma as defined by microvessel density (MVD) after immunohistochemical staining for Factor VIII and CD31. Libyan. J. Med. 2011, 6, doi:10.3402/ljm.v6i0.6016. 46.
48. Goebell, P.J.; Groshen, S.G.; Schmitz-Dräger, B.J.; International Study-Initiative on Bladder Cancer (ISBC). p53 immunohistochemistry in bladder cancer- a new approach to an old question. Urol. Oncol. 2010, 28, 377-388.
49. Lara, P.C.; Rey, A.; Santana, C.; Afonso, J.L.; Diaz, J.M.; González, G.J.; Apolinario, R. The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Radiother. Oncol. 1998, 49, 163-167.
50. Federico, A.; Morgillo, F.; Tuccillo, C.; Ciardiello, F.; Loguercio, C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer 2007, 121, 2381-2386.
51. Coyle, C.H.; Philips, B.J.; Morrisroe, S.N.; Chancellor, M.B.; Yoshimura, N. Antioxidant effects of green tea and its polyphenols on bladder cells. Life Sci. 2008, 83, 12-18.
52. Piloto, N.; Teixeira, H.M.; Teixeira-Lemos, E.; Parada, B.; Garrido, P.; Sereno, J.; Pinto, R.; Carvalho, L.; Costa, E.; Belo, L.; et al. Erythropoietin promotes deleterious cardiovascular effects and mortality risk in a rat model of chronic sports doping. Cardiovasc. Toxicol. 2009, 9, 201-210.
53. Kelsey, K.T.; Hirao, T.; Schned, A.; Hirao, S.; Devi-Ashok, T.; Nelson, H.H.; Andrew, A.; Karagas, M.R. A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. Br. J. Cancer 2004, 90, 1572-1576.
54. Lopez-Beltran, A.; Luque, R.J.; Alvarez-Kindelan, J.; Quintero, A.; Merlo, F.; Requena, M.J.; Montironi, R. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: The role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am. J. Clin. Pathol. 2004, 122, 444-452.
55. Taylor, J.A., III; Kuchel, G.A.; Hegde, P.; Voznesensky, O.S.; Claffey, K.; Tsimikas, J.; Leng, L.; Bucala, R.; Pilbeam, C. Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice. BMC Cancer 2007, 7, 135.